Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the industrial segment, followed by Agriculture.
🤖 AI Earnings Analysis
Evogene’s Q2 was weak despite a tiny revenue beat: sales were just **$347K** and still fell sharply year over year, while EPS missed by **$0.36** to **-$0.63**. In biotech, the lack of any catalyst and a **-220%** margin signal ongoing cash-burn pressure, not a turnaround.
